Multidrug resistance reversal activity of key ningalin analogues.
Key analogue derivatives of the ningalins, potent multidrug resistance (MDR) reversal compounds, were examined resulting in the discovery of a potent MDR reversal agent that hypersensitizes P-gp resistant tumor cell lines to front-line conventional therapeutic agents.
The Scripps Research Institute and the Skaggs Institute for Chemical Biology, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.
Danielle R
DR
Soenen
Inkyu
I
Hwang
Michael P
MP
Hedrick
Dale L
DL
Boger
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000187:drug effects; D000970:Antineoplastic Agents / Q000494:pharmacology; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004317:Doxorubicin / Q000494:pharmacology; D018432:Drug Resistance, Multiple / Q000187:drug effects*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D006575:Heterocyclic Compounds, 3-Ring / Q000138:chemical synthesis* / Q000494:pharmacology*; D006801:Humans; D013329:Structure-Activity Relationship; D014747:Vinblastine / Q000494:pharmacology
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000970:Antineoplastic Agents; D006575:Heterocyclic Compounds, 3-Ring; C409782:ningalin B; D014747:Vinblastine; D004317:Doxorubicin